Statins work because we solved blood-based risk stratification for cardiovascular disease decades ago. Measure LDL, treat if it's high, prevent the event. Cancer prevention has never had that kind of molecular handle. A 14-protein plasma signature, trained on 48,000+ UK Biobank participants and validated across eight independent cohorts, now predicts lung cancer more than five years before diagnosis. The proteins are not shed by a tumor. They reflect an inflammatory pre-disease state in lung tissue, upstream of cancer itself. When Swanton's team re-analyzed the CANTOS trial, identifying high-signature individuals for anti-inflammatory treatment cut the number needed to treat to 55. That is statin-level precision applied to cancer prevention. The pattern keeps repeating across disease categories: blood-based molecular surveillance, applied early enough, turns detection into prevention. The measurement science is arriving. The system to deliver it to individuals is not. Pandya, Zagorulya et al. Cell, 2026. 🧬

Most people treat sleep as a habit to discipline. You chase more hours and a better score in the morning, and you grade yourself on whether you hit them. The frontier of sleep science has quietly moved somewhere else. Sleep is not a behavior to fix. It is one of the highest-resolution biological signals your body produces, every night, for free, and most people read it at the shallowest possible layer. Here is what the research actually says. Start with the one metric everyone optimizes, the number of hours. In UK Biobank data, that is not even the number that best predicts mortality. The regularity of your sleep timing predicts how long you live better than its duration does (Windred et al., 2024). The thing most people track turns out not to be the thing that matters most. The reason is that sleep carries far more information than a single number. The Human Phenotype Project recorded 448 distinct sleep parameters from more than 16,000 nights of home monitoring across 6,366 adults, and from them predicted body measures spanning 15 of the 16 organ systems they examined, with visceral fat the single strongest correlate. At the data level, a night of sleep is a readout of how your whole body is doing. There is real biology underneath this. During deep sleep the brain runs a clearance system that flushes metabolic waste, including the proteins implicated in neurodegeneration. Work in Cell mapped how that clearance is driven, though the clearest mechanistic evidence is still in animal models (Hauglund et al., 2025). Deep sleep is doing measurable biological work even while everything looks switched off. The relationship also has an optimum. In large UK Biobank analyses, cognitive and mental health outcomes peak around seven hours, with both short and long sleep doing worse (Li et al., 2022). A signal with an optimum is exactly the kind of thing a single dashboard number fails to capture. And the baseline you measure against is not universal. Across 220,000 wearable users in 35 countries, East Asians slept shorter, later, and with lower efficiency than people in Western Europe and North America (Willoughby et al., 2023). The familiar advice to get eight regular hours was calibrated to a different population than the one a lot of people in this region actually live in. Put it together. The hours you track are not the metric that matters most. The signal is dense with information, it does measurable biological work, it has a sweet spot rather than a maximum, and its baseline shifts with where you live. So the useful question stops being whether you slept enough last night. It becomes what your sleep is telling you about where your metabolism and your heart are heading, and whether anything is reading it continuously. The shift from a score to a signal is the whole game. 🧬

Most high-performers run on a simple assumption, that more inputs mean better outputs. More sleep, more protein, more cold plunges, more NAD+. Biology doesn't read its inputs that way. Almost every variable has a window, not a slope. Nature this week added sleep to a long list. The MULTI Consortium analyzed 23 biological ageing clocks across imaging, plasma proteomics, and metabolomics in the UK Biobank. A consistent U-shape emerged across nine organ systems. The lowest biological age gaps land between 6.4 and 7.8 hours of sleep, with the optimum shifting by organ and by sex. Below 6 hours and above 8 hours both track to higher disease incidence and higher all-cause mortality. The interesting question is no longer how much sleep. It's where your window is. Self-reported sleep is the methodological limitation here, so the 6.4-7.8 range is directional rather than prescriptive. The bigger pattern is robust. Your biology runs on dose-response. What's missing is the infrastructure to find your individual window. 🧬

The most oxygen-deprived tissue in your body ages the slowest. That is not a typo. Your intervertebral disc lives in permanent hypoxia from birth. Most organs only run into low oxygen locally as they age, and when they do, a protein called HIF-1α builds up and accelerates cellular aging. The disc faces the same low-oxygen environment its entire life, yet keeps HIF-1α levels low and stable at every age. A team at Naval Medical University (Nature Aging, yesterday) showed why: the disc runs a selective autophagy pathway that continuously clears HIF-1α before it can accumulate. It solved a problem other organs never had to deal with until they started getting old. The interesting part is what they did next. They built a small molecule called HATC that mimics the disc's clearing trick, gave it to aged mice weekly, and watched HIF-1α drop across multiple organs within two weeks. Median lifespan went up about 14 percent, maximum lifespan about 12 percent. These are mouse numbers. HIF-1α also does essential work in wound healing and blood vessel formation, so turning it down body-wide in humans is not straightforward. But the logic of the approach is what stays with you: find the tissue that ages slowest, reverse-engineer the mechanism, and export it outward. That is not how most drug discovery works. Maybe it should be.

Thousands of people take rapamycin to live longer. Most of them also exercise. A new randomized controlled trial just showed that combining the two might be worse than exercise alone. The RAPA-EX-01 trial, published in the Journal of Cachexia, Sarcopenia and Muscle, put 40 adults aged 65 to 85 through a 13-week resistance and endurance program. Half received 6mg of weekly rapamycin, half received placebo. The researchers expected the drug to enhance exercise adaptations based on promising animal data. It did the opposite. The rapamycin group gained fewer chair-stand repetitions and showed trends toward reduced walking distance and grip strength compared to placebo. The drug arm also carried nearly 60 percent more adverse events. The mechanism is straightforward. Exercise builds muscle by activating a pathway called mTORC1. Rapamycin extends lifespan in animal models by suppressing that exact same pathway. When you stack both interventions, they pull in opposite directions at the same molecular switch, and in this trial, combining them gave back less than exercise alone. This is what treating longevity as a collection of independent supplements and protocols looks like when two of them share a biological bottleneck that no one modeled. Important context: this was an exploratory trial with 40 participants over 13 weeks, using one specific dose and timing protocol. It is not the final word. But the structural lesson holds regardless of where the dose-response curve eventually lands. If your two strongest longevity tools can fight each other because no one mapped the interaction, the problem is not the tools. The problem is that no one is managing the system. 🧬

The average American lives to 79 but loses their health at 64. That is fifteen years where your body is still here but your healthspan has already ended. @EricTopol 's team at Scripps sequenced the genomes of people over 80 who never developed a major chronic disease. They published the results in Cell. The finding was not that genetics are irrelevant. They identified protective factors for Alzheimer's and heart disease. But the known longevity gene variants explained almost nothing. What separated these healthy agers was a cluster of familiar, modifiable variables: exercise patterns, sleep architecture, inflammatory load, immune function, social connection. Every one of these is measurable today. Not a single one is being managed with any real infrastructure. Topol told last week that AI's most important contribution to medicine will be prevention. He is right about the direction. But the harder question is who builds the layer between what science already knows about these variables and what any individual can actually do with them on a Tuesday morning. That layer does not exist yet. The fifteen-year gap is what it costs to keep waiting.

Your annual checkup tests roughly 20 blood markers. It looks for what is already broken. Stanford's Wyss-Coray lab took a different approach. Using plasma proteomics across 5,676 adults, they measured organ-specific aging in 11 systems. Among older adults in the cohort, one in five had at least one organ aging significantly faster than the rest of their body. Those with accelerated heart aging faced 250% higher heart failure risk. The models are strongest in middle-aged and older populations; extending them to younger adults is an active area of research. None of this shows up on a standard panel. Not because the science doesn't exist. Because the infrastructure to deliver it at the individual level doesn't. The checkup was built for a world where you wait for symptoms. The science has moved on. The question is whether your health system has. (Oh et al., Nature 2023)

Omega-3 is probably the most studied and most argued-about molecule in nutrition science. In 2018, REDUCE-IT showed that pure EPA cut cardiovascular events by 25%. Two years later, STRENGTH tested EPA+DHA and found zero benefit. The field split into camps arguing about formulations, doses, and whether the mineral oil placebo in REDUCE-IT had inflated the result. But there is a more fundamental problem that none of these trials addressed: they measured what people swallowed, not what ended up in their tissues. In VITAL, giving 840mg of EPA+DHA per day only raised plasma levels by about 55%. If someone's baseline was already decent from diet, the supplement barely changed their biology. When a trial comes back negative, we genuinely cannot tell whether the molecule failed or whether the intervention was too small to matter. A consortium called FORCE took a different approach. Instead of running another supplement trial, they pooled individual-level blood measurements from 17 prospective cohorts across 10 countries. Among 42,466 people followed for a median of 16 years, those with the highest circulating EPA+DHA had 15 to 18% lower risk of dying from any cause (Harris et al., Nature Communications 2021). Last year, the same group extended this with UK Biobank data, bringing the total to over 160,000 individuals and 24,000 deaths. The association held and got stronger: 17% lower all-cause mortality, 21% lower cardiovascular mortality, 19% lower cancer mortality (O'Keefe, Harris et al., Mayo Clinic Proceedings 2024). Plant-derived omega-3 from flaxseed and walnuts showed no association in either analysis. Only marine-derived long-chain omega-3s carried the signal. What makes this more than an epidemiological number is the mechanism story converging from multiple directions. In coronary disease patients, higher EPA+DHA blood levels tracked with significantly slower telomere shortening over five years (Farzaneh-Far et al., JAMA 2010). In animal models, these fatty acids inhibit mTOR signaling, the same nutrient-sensing pathway targeted by rapamycin. They produce specialized pro-resolving mediators (resolvins, protectins) that actively resolve inflammation rather than just suppressing it. The omega-3 story was never really a supplement story. It was a tissue-level aging biology story that we kept trying to answer with pill-counting trials.

Psilocybin extended survival in aged mice by 30% last year. Since then, it has been widely called a longevity therapy. A new correspondence in npj Aging (Lerer, 2026) just asked what should have been the first follow-up. Is there any signal, at the population level, that people who use psychedelics actually live longer? The short answer is that we cannot tell yet. Lerer compared lifespans of 11 psychedelic advocates with 12 cancer researchers and 5 aging researchers. All three groups outlived population averages, which is exactly what you would expect from highly educated, high-income professionals. Psychedelic users did not outlive the others. The study is small and observational, so it proves nothing definitive. But it points to something worth noticing: between the rodent data and the early individual self-experiments that have followed, nobody has checked whether a human population signal even exists. The mouse data is genuinely interesting, and the self-experiments tracking short-term biomarker responses are adding real observations. But it is worth being clear about where the evidence actually stands. There is a plausible biological mechanism from rodent studies. There are short-term biomarker snapshots from a handful of individuals. What does not exist yet is any controlled human evidence on whether psilocybin affects lifespan or long-term healthspan. That gap should not be filled with conclusions. It should be filled with studies.

Cell published a framework this week that reframes how we think about cancer risk. The argument: "age at diagnosis" is the wrong metric. It tells you when disease appeared. It says nothing about when it started building. Risk is not an event. It's a trajectory. One that begins accumulating years before any symptom shows. Past exposures, including inflammation, metabolic stress, environmental insults, get encoded through epigenetic and metabolic reprogramming. They don't clear when the exposure ends. Plasma proteomics can now read those signatures. Organ-specific aging markers appear in blood before clinical disease does. The aging clock is ticking in your tissues before your doctor has anything to measure. And there's a window. Before tissue damage consolidates into what the authors call a functional "point of no return," targeted interception can shift the trajectory. After that point, the same interventions accomplish far less. We don't need to wait for a diagnosis to act. We need to know our biological state. Continuously. Before the window closes.